The U.S. Food and Drug Administration (FDA) has been actively greenlighting a number of efforts over the last few days to push therapies for rare or serious diseases that have largely unmet medical needs. Here’s a look at today’s approvals.
SAGE Therapeutics received a Fast Track designation from the FDA for its potential Huntington’s Disease (HD) drug. SAGE-178 is being developed as a treatment for HD after studies showed it helped improve cognitive performance, especially in terms of executive functioning.
“We believe that improving cognitive function is one of the core paths to maintaining quality of life in HD and remains an area of significant unmet medical need. The FDA Fast Track Designation is an important milestone in the development of SAGE-718, as it provides opportunities to engage collaboratively with the FDA to further clinical development and future regulatory review of SAGE-718 for the treatment of HD,” said Jim Doherty, Ph.D., chief research officer at Sage.
Pulmocide was also granted a Fast Track designation for opelconazole, its drug candidate for invasive pulmonary aspergillosis. The latter also received Orphan Drug and Qualified Infectious Disease Production designations.
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.
Stock image by @stockasso a from Depositphotos